Bivalirudin vs Epitalon
Overview
Bivalirudin is primarily a cardiovascular peptide, while Epitalon is used for anti-aging & longevity.
This page compares Bivalirudin and Epitalon across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Epitalon | |
|---|---|---|
| Category | Cardiovascular | Anti-aging & Longevity |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | 5-10 mg |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | cycle |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Telomere lengthening, improved sleep quality, enhanced longevity markers, circadian rhythm regulation |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Very well-tolerated. Minimal side effects during cycles |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Epitalon falls under Anti-aging & Longevity. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Epitalon: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Epitalon is typically dosed at 5-10 mg (cycle).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Epitalon has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Epitalon?
- Bivalirudin is primarily a cardiovascular peptide, while Epitalon is used for anti-aging & longevity. Bivalirudin is FDA-approved for one or more indications, whereas Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Epitalon used for?
- Longevity, telomere support.
- Can you take Bivalirudin and Epitalon together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Epitalon has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Epitalon FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Epitalon — full monograph: mechanism, research, dosing & references